Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland

Gibbs, J. Simon R.
March 2008
Heart;Mar2008 Supplement 1, Vol. 94, pi1
Academic Journal
The article provides information on the consensus statement concerning the major advancement in pulmonary hypertension (PH) management in clinical practice in Great Britain and Ireland. It has been noted that the purpose of the consensus statement is to update the 2001 recommendations to contemplate contemporary clinical practice management.


Related Articles

  • FDA EXTENDS TIMELINE FOR COMPLETION OF REMODULIN PHASE IV.  // Biotech Business;Oct2003, Vol. 16 Issue 10, p5 

    Reports that United Therapeutics Corp. has announced that the U.S. Food and Drug Administration has issued timelines for completion of a required Phase IV postmarketing study to further assess the clinical benefits of Remodulin, United Therapeutics' approved therapy for pulmonary arterial...

  • Remission of precapillary pulmonary hypertension in systemic lupus erythematosus. Ribeiro, João M.; Lucas, Margarida; Victorino, Rui M. M. // Journal of the Royal Society of Medicine;Jan2001, Vol. 94 Issue 1, p32 

    The article presents a clinical case report which reveals the remission of precapillary pulmonary hypertension in systemic lupus erythematosus (SLE). Clinical findings of patients with pulmonary hypertension and SLE have identified 16 antiphospholipid antibodies which are associated with...

  • Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safely, tolerability, clinical, and haemodynamic effect. D'Alto, M.; Vizza, C. D.; Romeo, E.; Badagliacca, R.; Santoro, G.; Poscia, R.; Sarubbi, B.; Mancone, M.; Argiento, P.; Ferrante, F.; Russo, M. G.; Fedele, F.; Calabrà, R. // Heart;May2007, Vol. 93 Issue 5, p621 

    Background: Oral bosentan is an established treatment for pulmonary arteral hypertension (PAH). Objective: To evaluate safety, tolerability, and clinical and haemodynamic effects of bosentan in patients with PAH related to congenital heart disease (CHD). Patients: 22 patients with CHD related...

  • An Update on Therapies for Pediatric Pulmonary Arterial Hypertension 2011. Yung, Delphine // Advances in Pulmonary Hypertension;Summer2011, Vol. 10 Issue 3, p109 

    The article provides updates in the treatment of pulmonary arterial hypertension (PAH) in children, highlighting the growing numbers of approved therapies for pulmonary hypertension. It examines the literature associated to pediatric use of those therapies and discusses the evidence-based...

  • Epoprostenol for severe pulmonary hypertension.  // Archives of Disease in Childhood;Aug2007, Vol. 92 Issue 8, p689 

    This article reports on the treatment of epoprostenol for severe pulmonary hypertension. The average survival period with untreated idiopathic pulmonary hypertension is 2.8 years in adults and 10 months in children. Successful treatment with epoprostenol was reported for children in 1999 and for...

  • Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Gibbs, J. Simon R. // Thorax;Mar2008 Supplement 2, Vol. 63, pii1 

    The article presents a consensus statement on the management of pulmonary hypertension in clinical practice in Great Britain and Ireland. It notes that the consensus statement reflects contemporary practice in the management of this rare and deadly, but now treatable condition, in the pulmonary...

  • Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia. Trembath, Richard C.; Thomson, Jennifer R.; Machado, Rajiv D.; Morgan, Neil V.; Atkinson, Carl; Winship, Ingrid; Simonneau, Gerald; Galie, Nazzareno; Loyd, James E.; Humbert, Marc; Nichols, William C.; Berg, Jonathan; Manes, Alessandra; McGaughran, Julie; Pauciulo, Michael; Wheeler, Lisa; Morrell, Nicholas W. // New England Journal of Medicine;8/2/2001, Vol. 345 Issue 5, p325 

    Background: Most patients with familial primary pulmonary hypertension have defects in the gene for bone morphogenetic protein receptor II (BMPR2), a member of the transforming growth factor β (TGF-β) superfamily of receptors. Because patients with hereditary hemorrhagic telangiectasia may...

  • Pulmonary hypertension after pulmonary emboli: an underrecognized condition. De Perrot, Marc; Granton, John; Fadel, Elie // CMAJ: Canadian Medical Association Journal;6/6/2006, Vol. 174 Issue 12, p1706 

    Provides information on chronic thromboembolic pulmonary hypertension (CTEPH). Symptoms of CTEPH; Methods used in diagnosing the disease; Treatment of choice for patients with CTEPH.

  • A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial. Elinoff, Jason M.; Rame, J. Eduardo; Forfia, Paul R.; Hall, Mary K.; Junfeng Sun; Gharib, Ahmed M.; Abd-Elmoniem, Khaled; Graninger, Grace; Harper, Bonnie; Danner, Robert L.; Solomon, Michael A. // Trials;2013, Vol. 14 Issue 1, p1 

    Background: Pulmonary arterial hypertension is a rare disorder associated with poor survival. Endothelial dysfunction plays a central role in the pathogenesis and progression of pulmonary arterial hypertension. Inflammation appears to drive this dysfunctional endothelial phenotype, propagating...


Read the Article


Sign out of this library

Other Topics